Table 1.

CP dosage during previously encountered coronavirus outbreaks along with the novel coronavirus.

disease and the causative agent	CP dose (volume)	antibody titre	summarized findings	references
SARS caused by SARS-CoV	279 ± 127 (160–640) ml 200 ml 500 ml 2 units of 250 ml each (total 500 ml)	NA NA IgG: >640 NA	—overall, 80 patients received CP; ten patients died —CP at approximately 14 (7–30) days following the onset of symptoms —good clinical outcome; by day 22, 33 patients were discharged from the hospital —improved outcome with early administration of CP —no adverse events	[49,67,87–89]
MERS caused by MERS-CoV	four transfusions of CP to three patients; volumes not stated 2 units (250–350 ml/unit) 250 ml	1:40 to 1:80 NA NA	—all three patients survived, questionable benefits —feasibility study to evaluate the ratio of convalescent donors having antibodies against MERS-CoV —case report of one patient —TRALI observed	[67,90–92]
COVID-19 caused by SARS-CoV-2	200 ml two consecutive transfusions of 200–250 ml (400 ml total)	neutralizing antibody titre: >1:640 ELISA anti-SARS-CoV-2—antibody titre: >1:1000 neutralizing antibody titre: >1:40	—uncontrolled, 10 severely ill patients, CP at 16.5 (11.0–19.3) days; recovery of all patients; no significant adverse effect —uncontrolled five critically ill cases, CP at 10–22 days after admission; recovery of all patients	[53,93]